Innate Pharma S.A. (IPHA)

Market Cap	212.73M -1.3%
Revenue (ttm)	10.57M -55.2%
Net Income	-57.74M
EPS	-0.65
Shares Out	93.79M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,207
Open	2.200
Previous Close	2.250
Day's Range	2.000 - 2.300
52-Week Range	1.170 - 2.630
Beta	0.75
Analysts	Buy
Price Target	6.97 (+230.33%)
Earnings Date	Mar 26, 2026

About IPHA

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 17, 2019
• Employees: 174
• Stock Exchange: NASDAQ
• Ticker Symbol: IPHA
• Website: https://www.innate-pharma.com

Financial Performance

In 2025, Innate Pharma's revenue was 9.01 million, a decrease of -55.25% compared to the previous year's 20.12 million. Losses were -49.18 million, -0.59% less than in 2024.

Financial numbers in EUR

Analyst Summary

According to 4 analysts, the average rating for IPHA stock is "Buy." The 12-month stock price target is $6.97, which is an increase of 230.33% from the latest price.

Price Target

$6.97

(230.33% upside)

Analyst Consensus: Buy